# Intravenous NAD+ drips

Source: https://onco.cc/technologies/rejuv-frontier-nad-infusions/  
OnCo record `rejuv-frontier-nad-infusions` (Technology). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

An NAD+ drip takes several hours, is sold in courses, and has never been tested against placebo for anything a cancer survivor would recognise. The published human literature on intravenous NAD+ amounts to retrospective series and narrative reviews.

## Summary

Intravenous nicotinamide adenine dinucleotide is sold by wellness clinics for fatigue, 'cellular repair', brain fog and recovery after treatment, typically as a course of infusions each lasting several hours because faster infusion causes chest tightness, nausea and flushing. A search of Europe PMC for randomised trials of intravenous NAD+ in cancer survivors returns none. What exists is a retrospective comparison of intravenous NAD+ against oral nicotinamide riboside and narrative reviews of its use in wellness settings, which describe practice rather than test it.

Oral precursors raise blood NAD+ reliably, as the NR-SAFE randomised trial showed, so the argument for an intravenous route rests on a bioavailability claim that has not been shown to translate into any outcome. The unresolved laboratory question about NAD+ availability to tumour cells applies here as much as to the oral form, and nothing human settles it.

The practical position: this is expensive, time-consuming, sold privately, and has no controlled evidence of benefit for anyone, let alone for someone recovering from cancer treatment. Cannulation in a person with a central line or a recent history of neutropenia is not a trivial procedure to have done outside a clinical setting.

## Fields

- Kind: Technology
- Status: emerging
- Last checked: 2026-10-02
- Tags: rejuvenation; survivorship; evidence:insufficient; unproven; supplement
- Principle: The claim is that infusion bypasses first-pass metabolism and delivers NAD+ intact. NAD+ is a large, charged molecule that is largely degraded extracellularly to nicotinamide before uptake, so what reaches cells is probably the same salvage substrate that an oral precursor supplies, which is why the route makes little pharmacological sense.
- Strengths: No serious safety signal reported in the small published series
- Limitations: No randomised controlled trial of intravenous NAD+ in cancer survivors for any outcome; Pharmacological rationale for the intravenous route is weak; Infusion reactions require slow administration over hours; Cannulation outside a clinical setting carries infection risk, which matters more after treatment; Sold privately as a course at a price, with claims no trial supports

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/Nicotinamide_adenine_dinucleotide
- Narrative review of intravenous NAD+ and NAD+ precursors in wellness and translational medicine (Front Aging 2026): https://doi.org/10.3389/fragi.2026.1887175
- Brakedal et al., NR-SAFE: a randomized, double-blind safety trial of high dose nicotinamide riboside in Parkinson's disease (Nat Commun 2023): https://doi.org/10.1038/s41467-023-43514-6

## Connected records

- technologies: [Alternative medicine used instead of standard treatment](https://onco.cc/technologies/alternative-medicine-instead-of-treatment/), [NAD+ precursors taken by mouth](https://onco.cc/technologies/rejuv-frontier-nad-precursors/), [What actually works after treatment](https://onco.cc/technologies/rejuv-frontier-what-works/)
- fronts: [Recovery & Rejuvenation](https://onco.cc/fronts/rejuvenation/), [Supportive Care & Survivorship](https://onco.cc/fronts/supportive-care/)
- drugs: [Nicotinamide](https://onco.cc/drugs/nicotinamide/)
- bottlenecks: [Survivorship and late effects are neglected](https://onco.cc/bottlenecks/b-survivorship/)

---
JSON: https://onco.cc/api/v1/entities/rejuv-frontier-nad-infusions.json